Zacks Investment Research recorded Galena Biopharma Inc (NASDAQ:GALE), raising its target price to $0.75 earlier today
- Updated: March 20, 2017
Zacks Investment Research increased the stock price target of Galena Biopharma Inc (NASDAQ:GALE) to $0.75 indicating a possible upside of 0.19%.
Previously on 2/6/2017, FBR & Co released a statement about Galena Biopharma Inc (NASDAQ:GALE) bumped down the target price from $11.00 to $4.00 that indicated a possible upside of 2.33%.
Yesterday Galena Biopharma Inc (NASDAQ:GALE) traded 0.46% higher at $0.63. The company’s 50-day moving average is $0.86 and its 200-day moving average is $1.21. The last stock close price is down -48.28% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. 2,836,041 shares of the stock were exchanged, up from an average trading volume of 2,668,230
See Chart Below
Galena Biopharma Inc has a 52 week low of $0.53 and a 52 week high of $49.80 The company’s market cap is currently $0.
Brief Synopsis On Galena Biopharma Inc (NASDAQ:GALE)
Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system to seek out and attack any residual cancer cells.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.